Enzyme-Linked Immunosorbent Assay to Quantify Targeting Molecules on Nanoparticles

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Therapeutics

Background:

• Molecular targeting improves cancer therapeutic specificity and reduces off-target effects.
• Nanoparticle-based treatments can be enhanced by targeting strategies for improved anticancer efficacy.

Purpose of the Study:

• To describe methods for conjugating antibodies to silica-gold nanoshells.
• To establish a quantitative assay for measuring antibody content on these nanoparticles.
• To provide a versatile method for enhancing nanoparticle drug delivery systems.

Main Methods:

• Conjugation of antibodies (e.g., anti-EGFR) to silica-gold nanoshells.
• Quantification of conjugated antibodies using a solution-based enzyme-linked immunosorbent assay (ELISA).
• Utilized anti-EGFR antibodies and gold-silica nanoshells as a model system.

Main Results:

• Successful conjugation of antibodies to silica-gold nanoshells was achieved.
• An ELISA method was developed to accurately quantify the amount of antibody on the nanoparticles.
• The described methodology is adaptable for various targeting antibodies and nanoparticle types.

Conclusions:

• The developed method enables precise quantification of antibody-conjugated nanoparticles.
• This approach is crucial for optimizing nanoparticle-based cancer therapies.
• The technique offers broad applicability for enhancing targeted drug delivery systems.